Market Potential



*Based on 2030 Revenue Projection



*Based on 2030 Revenue Projection
Adiflo devices have been designed to integrate directly into existing regenerative medicine and adipose processing workflows through a scalable system built for clinical efficiency and repeat procedural use.
Our commercialization strategy initially targets plastic surgery clinics, regenerative medicine centers, and high-volume surgical facilities seeking standardized, high-throughput adipose tissue processing.
The system uses replaceable EMD and RefineX processing components that clinics routinely purchase for repeated procedures. This approach supports sterility, consistency, and long-term operational scalability while lowering adoption barriers through integration with existing clinical infrastructure.
As more clinics adopt the Sayenza and Adiflo platform, continued use of replacement components and partnerships with clinical organizations will help drive long-term growth across regenerative medicine applications.
Growth Flywheel
Platform Adoption
Clinics deploy Sayenza
Repeat Purchases
EMD + RefineX refills
Partnerships
Clinical organizations
Market Expansion
New regen. applications
Drop-In Integration
By combining the core Sayenza platform with replaceable processing components, the system lowers adoption barriers through integration with existing clinical infrastructure.
Reproducible Performance
The system supports reproducible performance, reduced workflow disruption, and scalable clinical adoption across regenerative medicine workflows.